

Release Date: March 4, 2026



LabGx and Portal Updates

Report & System Enhancements

New Features


- **Filter Flagged Reports**
- **New Extended Raw Report**

Enhancements

- **Enhanced User Management**
- **Improvements to RXCUI medication matching**
- **New Medical Record Number Field**
- **New Section for Unknown Medications**
- **Changes to Select Column Names in Lab Report**
- **Updates to Drug-Gene Interactions for PGx Reporting**
- **Panel Support for Smart Mapping**

Enhanced User Management

We have introduced enhancements to User and License Management to provide greater flexibility and administrative control. When sharing a license invite, assign a Clinic Identifier, Clinic Type, and Clinic Instance, plus enable shared access immediately. While selecting the Clinic Identifier, the appropriate clinic instance must be selected from the dropdown, and clinic instances can be configured for affiliated laboratories too.



The image shows two screenshots of the GenXys interface. The left screenshot shows the 'TreatGx' window with fields for License Owner, License User, Expiry Date, Trial, Invited User, Email, Clinic Identifier, Clinic Type, Clinic Instance, and Shared Access. The Clinic Identifier dropdown is open, showing options: None, AffLab1, afflab2, and DemoLab. The right screenshot shows a detailed form for license assignment with fields for Email (Test@email.com), Clinic Identifier (DemoLab), Clinic Type (Demo-Lab), Clinic Instance (1234567), and Shared Access (toggle switch). The 'Assign License' button is highlighted with a red box.

Administrators retain the ability to modify the Clinic Type, Clinic Instance, or shared access settings at any time after the license has been assigned. New user accounts auto-verify on sign-up for immediate access, skipping the manual approval.

How the shared account works

The shared access feature lets multiple users view reports under a common Clinic Type, while maintaining individual identifiers through Clinic Instance (typically the user's NPI number).

The **Clinic Type** is used to create a shared group of users. The Clinic Instance (usually the NPI) uniquely identifies each user within that group and ties orders or cases to a specific healthcare provider (HCP).

When assigning a case, both the Clinic Type and Clinic Instance are used to ensure the report is directed to the correct provider. However, if multiple users share the same Clinic Type and have **Shared Access enabled**, they are able to view each other's assigned cases and reports within that shared group.

Example:

- Users A, B, and C share Clinic Type: Demo-Lab.
- Each user has unique Clinic Instance (e.g., their individual NPI).
- Shared Access is enabled for Users A and C: they see each other's assigned cases and reports.
- Shared Access is not enabled for User B: B will see reports assigned to A or C. This allows reports to be shared across multiple users within the same clinic group while maintaining individual provider identification and administrative control.

Improvements to RXCUI medication matching


RXCUI medication matching in LabGx has been improved for enhanced accuracy, consistency, and reliability. The updated logic maps medications to RXCUI codes more precisely, reducing mismatches and improving standardization across the platform.

Filter Flagged Reports

LabGx now includes a new filtering capability for flagged reports to streamline troubleshooting. You can filter reports by specific flagged reasons, such as **Medication Mismatch – Flagged or Genetic Mismatch/Unreported – Flagged**. This helps users managing high report volumes quickly identify, categorize, and resolve issues.

To use this filter:

1. Navigate to Filter section in LabGx
2. Select the desired filter from the filter options.



New Extended Raw Report

A new Extended Raw Report provides more comprehensive genetic and medication insights. It includes **Drug-Gene Interaction (DGI) messages, current medications, report medications, recommended medications with severity levels, and a detailed phenotype table with star alleles**. Labs gain deeper clinical transparency and insights into report data.

This is available as an **add-on option** for laboratories interested in enabling it

```
"ReportedMedications": [
  {
    "Name": "Abrocitinib",
    "EffectPhenotypes": [
      {
        "DerivedGenetics": [
          {
            "TestName": "CYP2C19",
            "Result": "*17/*38"
          }
        ],
        "DrugEffectPhenotype": "Rapid metabolizer",
        "Evidence": "FDA 1<sup>46</sup>;Product monograph (actionable)<sup>36</sup>"
      }
    ],
    "HasDgi": true,
    "MaxSeverity": 1,
    "Notes": "Mild or no drug-gene interaction: no PGx-based action; standard precautions apply"
  },
  {
    "Name": "E2/E4",
    "Gene": "APOE",
    "DerivedFrom": "RS429358, RS7412",
    "Phenotype": "E2/E4 Heterozygous",
    "ActivityScore": "N/A"
  },
  {
    "Name": "*1/*6 or *4/*9",
    "Gene": "CYP2B6",
    "DerivedFrom": "RS28399499, RS3211371, RS34223104, RS2279343, RS3745274, RS12721655",
    "Phenotype": "Intermediate Metabolizer",
    "ActivityScore": "N/A"
  },
  {
    "Name": "G/G",
    "Gene": "CYP2C (rs12777823)",
    "DerivedFrom": "RS12777823",
    "Phenotype": "Typical response to warfarin (no change in PGx-related dose requirement)",
    "ActivityScore": "N/A"
  }
],
"ConsideredMedications": [],
"CurrentMedications": [],
"Genotypes": [
  {
    "Gene": "ABCG2",
    "RSID": "rs2231142",
    "HGVS": "g.105152C>A",
    "HGVSReference": "NG_032067.2",
    "GenotypeConverted": "",
    "GenotypeOriginal": "G/G"
  },
  {
    "Gene": "APOE",
    "RSID": "rs429358",
    "HGVS": "g.7903T>C",
    "HGVSReference": "NG_007084.2",
    "GenotypeConverted": "",
    "GenotypeOriginal": "C/T"
  }
]
```

New Medical Record Number Field

A new MRN (**Medical Record Number**) Field enhances patient tracking in reports. Labs can optionally include MRN when submitting patient data. If included, the MRN will appear in the **report header**, making it easier to link reports to patient records.

To enable this feature:

1. Go to **Lab Studio**
2. Under **Header** section, check the **Include MRN** option.

To review order specifications for including the MRN, [click here](#)

PATIENT INFORMATION	SPECIMEN DETAILS	OI
NAME: Sample2First Sample2Last MRN: 999-777-555-333-111 DOB: 01/Jan/1988 SEX AT BIRTH: Female ETHNICITY: AST (Assiniboine and Sioux Trib... TreatGx ReviewGx	BARCODE: DEMO1001 SAMPLE ID: Sample A TYPE: Swab COLLECTED: 11/May/2023 QUALITY: Needed to extract the sample three...	S/ GI (P

Patient Profile:

- ☒ Include hyperlink to ReviewGx patient case
- ☒ Include hyperlink to TreatGx patient case
- ☒ Include Medical Record Number

New Section for Unknown Medications

A new **Unknown Medication** section has been added to the report to improve visibility of unmatched medications. This section lists current medications that could not be matched and therefore were **not analyzed for Drug-Gene Interactions (DGI)**. Previously omitted, providers can now see if these medications are part of the patient's current regimen, even if they are not analyzed. This enhancement provides a more complete view of the patient's medication profile.

Unknown Medications

These medications were excluded from analysis for drug-gene interactions, drug-drug interactions, and renal or hepatic considerations due to an unknown medication record. Common reasons include discontinued medications, alternative naming conventions, or data entry variations. The medication name is displayed as entered.

- acetaminophen / hydrocodone bitartrate [Norco]
- Adderall
- amoxicillin / clavulanate [Augmentin]
- Fioricet
- sitagliptin phosphate [Januvia]
- Suboxone
- Trelegy

Note: These medications were excluded from analysis for drug-gene interactions, drug-drug interactions, and renal or hepatic considerations due to an unknown medication record. Common reasons include discontinued medications, alternative naming conventions, or data entry variations. The medication name is displayed as entered.


Panel Support for Smart Mapping

Announcing support for multiple panels in Lab Studio PGx Panel Mapping for flexible, client-specific deployment.

This enhancement makes it easier for laboratories to update existing panels and create new ones with the same flexibility used to build Lab Studio templates.

By selecting a reporting template, you can now create, customize, and deploy new panels directly within the selected template workflow. SupportBot is available to guide Lab Directors through this step-by-step.

Post-mapping, download Allele Coverage, Ambiguity Report and GeneDrugList.



To use the new panel mapping, your order.JSON file must be configured to include the panel ID in the `panel` parameter.

```
"panel": "MOLDX"
```

Please contact GenXys regarding validation requirements for any newly deployed panel.

Note: Only active Lab Directors are authorized to deploy mappings.

Changes to Select Column Names in Lab Report

Laboratory Report table fields now use updated, clinically precise terminology. HGVS column has been renamed to **Allele Definition**, and HGVS Reference has been renamed to **Allele Information Reference**.

Laboratory Report

The **Laboratory Report** contains your genetic results.

Gene	rsID	Genomic Location	Allele Information	Allele Information Reference	Result
CYP2B6	rs34223104	chr19:41497129	g.41497129T>C	NC_000019.9	T/T
CYP2B6	rs34883432	chr19:41497272	g.41497272A>T	NC_000019.9	A/A
CYP2B6	rs8192709	chr19:41497274	g.41497274C>T	NC_000019.9	C/C
CYP2B6	rs33973337	chr19:41497286	g.41497286A>T	NC_000019.9	A/A
CYP2B6	rs33980385	chr19:41497293	g.41497293A>G	NC_000019.9	A/A
CYP2B6	rs33926104	chr19:41497305	g.41497305C>A	NC_000019.9	C/C

☒ Include Genomic Locations

Genomic Location Reference

Genomic Location

Genomic Location

Genomic Location (hg19)

Genomic Location (GRCh37)

Genomic Location (GRCh38)

Genomic Location column has been enhanced to reflect laboratory-reported information. Laboratories can now specify which genomic reference was used when reporting results providing greater flexibility and more accurate representation of genomic data. Available options include **GRCh38**, **GRCh37**, **hg19**, and **RefGeneSeq**.

Technical Report

☒ Include Genomic Locations

Genomic Location Reference

Genomic Location

☒ Include Genotype Result

☒ Include Allele Information

☒ Include Allele Information Reference

☒ Include RSID

☒ Include Phenotype Definitions

☒ Include Activity Scores

Expanded customization options within LabStudio is now available, giving laboratories greater control over how information is displayed in the Laboratory Report table. Select columns like **RSID**, **Genomic Location**, **Allele Information**, **Allele Information Reference**, **Genotype Result** to fit your workflow.

Updates to Drug-Gene Interactions for PGx Reporting

Buprenorphine drug-gene interaction content is now available for panels testing CYP3A4 rs2740574, based on ClinPGx (PharmGKB) Level 3 evidence. Learn more: <https://www.clinpgx.org/combo/PA130,PA448685/summaryAnnotation>

Buprenorphine	Phenotype	Genetic Test	Results	Source/Evidence Level
Belbuca Brixadi Butrans Sublocade Suboxone Zubsolv  ReviewGx	Possible increased dose requirement to prevent withdrawal symptoms, and decreased analgesic response, compared to T/T	CYP3A4 rs2740574	C/C	PharmGKB 3 ^{47,48}
Drug-Gene Interactions:				
Moderate drug-gene interaction: may require an increased dose, may reduce efficacy				
 PharmGKB – Clinical Annotation (Level 3 Dosage): Patients with opioid-related disorders and the CYP3A4 rs2740574 C/C genotype may require an increased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the T/T genotype. Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.				
 PharmGKB – Clinical Annotation (Level 3 Efficacy): Patients with the CYP3A4 rs2740574 C/C genotype who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the T/T genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.				

Coming Soon

Updates to thiopurine guidance (azathioprine, mercaptopurine, thioguanine) aligned with CPIC’s February 2026 guideline update, along with associated TPMT and NUDT15 mapping updates where applicable. Overall dosing guidance remains consistent with prior recommendations, with a few minor updates. The update also provides clearer alignment of recommendations for malignant vs. non-malignant indications for each of the three thiopurines. Learn more: <https://blog.clinpgx.org/cpic-guideline-for/>